Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · IEX Real-Time Price · USD
962.49
-3.81 (-0.39%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Regeneron Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 1995
Net Income
3,9544,3388,0753,5132,1162,4441,199895.5636.06338.13
Upgrade
Depreciation & Amortization
421341.4286.2235.9210.3148.2145.5104.774.9152.69
Upgrade
Share-Based Compensation
885725601.7432464.3427.4507.3559.9459.05321.75
Upgrade
Other Operating Activities
-665.6-389.9-1,881.9-1,563-360.4-824.9-544.2-74.2160.7739.87
Upgrade
Operating Cash Flow
4,5945,0157,0812,6182,4302,1951,3071,4861,331752.44
Upgrade
Operating Cash Flow Growth
-8.39%-29.18%170.47%7.74%10.70%67.94%-12.03%11.66%76.86%27.84%
Upgrade
Capital Expenditures
-718.6-590.1-551.9-614.6-429.6-383.1-272.6-511.9-677.93-333.01
Upgrade
Acquisitions
-262.7-1,257.100000000
Upgrade
Change in Investments
-2,203.8-1,937.4-4,832.8544-1,598.2-1,069.9-732.6-534.9-229.67-87.77
Upgrade
Other Investing Activities
------10----
Upgrade
Investing Cash Flow
-3,185.1-3,784.6-5,384.7-70.6-2,027.8-1,463-1,005.2-1,046.8-907.6-420.78
Upgrade
Share Issuance / Repurchase
-1,790.1-1,009-1,005.8-3,952.4-252.1-77.1-61.5-16.545.82-141.54
Upgrade
Debt Issued / Paid
0001,9820037.1-40.6-140.45-221.73
Upgrade
Other Financing Activities
--------643.4-168.17144.73
Upgrade
Financing Cash Flow
-1,790.1-1,009-1,005.8-1,970.5-252.1-77.1-24.4-700.5-262.8-218.55
Upgrade
Exchange Rate Effect
-0.4000000000
Upgrade
Net Cash Flow
-381.6221.3690.8577150.1655277.5-261.4160.38113.11
Upgrade
Free Cash Flow
3,8754,4256,5292,0042,0001,8121,035974652.85419.43
Upgrade
Free Cash Flow Growth
-12.42%-32.23%225.90%0.15%10.40%75.16%6.21%49.19%55.65%-2.97%
Upgrade
Free Cash Flow Margin
29.54%36.35%40.63%23.58%30.51%35.21%17.62%20.04%15.91%14.88%
Upgrade
Free Cash Flow Per Share
36.3241.3161.7718.6218.3216.799.739.306.334.17
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).